Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 15;9(7):e002707. doi: 10.1136/jitc-2021-002707

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Intratumorally administered PeptiBAC induces systemic tumor-specific T cell responses in a syngeneic mouse model of B16.OVA melanoma. (A) BCG, peptides alone or PeptiBAC-OVA was given intratumorally 12, 15 and 22 days post tumor implantation. Individual tumor growth curves for all treatment groups are shown. A threshold of 250 mm³ was set to define the percentage of mice responding to the different therapies (dotted line). The percentage of responders in each treatment group is shown on the right side of the dotted line. (B) Immunological analysis of tumors and spleens of treated mice. (C) Kaplan-Meier survival curve for the treatment groups. The number of mice in each group was 7–8. Statistical analysis was performed with one-way analysis of variance. ***p<0.001. OVA, ovalbumin; PeptiBAC, peptide-coated Bacillus Calmette-Guérin; PeptiBAC-OVA, OVA-targeting PeptiBAC.